On March 10, 2010
FDA Issues Rare Quadruple Warning to Kidney Drug Maker; Next Up, Double-Secret Probation
It’s considered serious when the FDA sends one of its “warning letters” to a drug company, which tend to outline one or two ways in which a company has pushed the envelope in its marketing. But Shire (SHPGY) received an
…
0 Comments